Abstract:Rationale: Low density cholesterol receptor (LDLR) in the liver is critical for the clearance of low-density lipoprotein cholesterol (LDL-C) in the blood. In atherogenic conditions, proprotein convertase subtilisin/kexin 9 (PCSK9) binds to LDLR on the surface of hepatocytes, preventing its recycling and enhancing its degradation in lysosomes, resulting in reduced LDL-C clearance. Our recent studies demonstrate that epsins, a family of ubiquitin-binding endocytic adaptors, are critical regulators of atherogenicity. Given the fundamental contribution of circulating LDL-C to atherosclerosis, we hypothesize that liver epsins promote atherosclerosis by controlling PCSK9-triggered LDLR endocytosis and degradation. Objective: We will determine the role of liver epsins in promoting PCSK9-mediated LDLR degradation and hindering LDL-C clearance to propel atherosclerosis. Methods and Results: We generated double knockout mice using albumin Cre in which both genes of epsin, namely, epsin 1 and epsin 2, are specifically deleted in the liver (Liver-DKO) on an ApoE -/- background. We discovered that western diet (WD)-induced atherogenesis was greatly inhibited, along with diminished blood cholesterol and triglyceride levels. Mechanistically, using scRNA-seq analysis on hepatocyte-derived data revealed elevated pathway involved in LDL particle clearance under WD treatment in ApoE -/- /Liver-DKO, which was coupled with diminished plasma LDL-C levels. Further analysis using the MEBOCOST algorithm revealed enhanced communication score between LDLR and cholesterol, suggesting elevated LDL-C clearance in the ApoE -/- Liver-DKO mice. In addition, we showed that loss of epsins in the liver upregulates of LDLR protein level. We further showed that epsins bind LDLR via the ubiquitin-interacting motif (UIM), and PCSK9-triggered LDLR degradation was abolished by depletion of epsins, preventing atheroma progression. Finally, our therapeutic strategy, which involved targeting liver epsins with nanoparticle-encapsulated siRNAs, was highly efficacious at inhibiting dyslipidemia and impeding atherosclerosis. Conclusions: Liver epsins promote atherogenesis by mediating PCSK9-triggered degradation of LDLR, thus raising the circulating LDL-C levels. Targeting epsins in the liver may serve as a novel therapeutic strategy to treat atherosclerosis by suppression of PCSK9-mediated LDLR degradation.

Hepatic inactivation of murine Surf4 results in marked reduction in plasma cholesterol

Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4

Inducible Global Knockout of Surfeit Locus Protein 4 in Adult Mice Results in Hypolipidemia, Intestinal Lipid Accumulation, Liver Injury, and Increased Mortality

Surf4 (Surfeit Locus Protein 4) Deficiency Reduces Intestinal Lipid Absorption and Secretion and Decreases Metabolism in Mice

Hepatic Surf4 Deficiency Impairs Serum Amyloid A1 Secretion and Attenuates Liver Fibrosis in Mice

Intestinal SURF4 is essential for apolipoprotein transport and lipoprotein secretion

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9.

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

Differential cholesterol uptake in liver cells: A role for PCSK9

SEC24A Deficiency Lowers Plasma Cholesterol Through Reduced PCSK9 Secretion

Hepatic S1P Deficiency Lowers Plasma Cholesterol Levels in Apob-Containing Lipoproteins when LDLR Function is Compromised.

Liver-specific knockdown of long-chain acyl-CoA synthetase 4 reveals its key role in VLDL-TG metabolism and phospholipid synthesis in mice fed a high-fat diet

Disruption of Phospholipid Transfer Protein-Mediated High-Density Lipoprotein Maturation Reduces Scavenger Receptor BI Deficiency-Driven Atherosclerosis Susceptibility Despite Unexpected Metabolic Complications

Receptor-Mediated ER Export of Lipoproteins Controls Lipid Homeostasis in Mice and Humans

PCSK9-D374Y Suppresses Hepatocyte Migration Through Downregulating Free Cholesterol Efflux Rate and Activity of Extracellular Signal-Regulated Kinase.

Hepatic deficiency of low density lipoprotein receptor-related protein-1 reduces high density lipoprotein secretion and plasma levels in mice

Abstract 4113300: Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis

Silencing of Mouse Hepatic Lanosterol 14-.ALPHA. Demethylase Down-Regulated Plasma Low-Density Lipoprotein Cholesterol Levels by Short-Term Treatment of Sirna

Heterozygous Ldlr-Deficient Hamster As A Model To Evaluate The Efficacy Of Pcsk9 Antibody In Hyperlipidemia And Atherosclerosis

Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice

SURF1 knockout cloned pigs: Early onset of a severe lethal phenotype